Dr. Matthew Matasar, MD
Dr. Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr. Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodkgin lymphoma. As a member of the lymphoma and BMT services, his research is aimed to explore the management of aggressive lymphomas, focusing on improving outcomes in relapsed but curable patients using novel therapy and stem cell transplantation techniques. His primary research interest is in developing a research program to better understand the optimal care of lymphoma survivors, focusing on reducing the risk and improving the management of late effects of chemotherapy and radiation therapy. He is the Chief of Medical Oncology at MSK Bergen, directing a team of expert medical oncologists in the delivery of cutting-edge care to patients at our outpatient center in Montvale, New Jersey.
Relevant Publications
Kara Franco , MPH, Elyse Shuk , MA, Errol Philip , PhD, Danielle Blanch-Hartigan , PhD, MPH, Patricia A. Parker , PhD, Matthew Matasar , MD, Steven Horwitz , MD, David Kissane , MD, Smita C. Banerjee , PhD & Carma L. Bylund , PhD Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis, journal of Psychosocial Oncology, Pages 513-530 | Accepted author version posted online: 30 Mar 2017, Published online: 30 Mar 2017 http://www.tandfonline.com/doi/full/10.1080/07347332.2017.1313352?scroll=top&needAccess=true
Talya Salz, Emily Craig Zabor, Peter de Nully Brown, Susanne Oksbjerg Dalton, Nirupa Jaya Raghunathan, Matthew J. Matasar, Richard Steingart, Henrik Hjalgrim, Peter Svenssen Munksgaard, Lena Specht, Andrew J. Vickers, Kevin C. Oeffinger, Christoffer Johansen The contribution of pre- existing cardiovascular (CV) risk factors to the risk of stroke or heart attack among non-Hodgkin lymphoma (NHL) survivors. Journal of Clinical Oncology, 10082, 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.10082
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877. [Epub ahead of print] PMID:28874350 http://www.bloodjournal.org/content/early/2017/09/05/blood-2017- 06-788877?sso-checked=true
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.PMID: 28314788 http://clincancerres.aacrjournals.org/content/early/2017/05/17/1078-0432.CCR-16-3068
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024. Epub 2016 Oct 3. PMID:27713090 http://www.sciencedirect.com/science/article/pii/S1083879116303871
Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS1, Briggs
S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro
Multicenter Phase II Study of Temozolomide and Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Newly Diagnosed Anaplastic Oligodendroglioma. Neuro Oncol. 2017 May 2. doi: 10.1093/neuonc/nox086. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28472509
Communication between Oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis. Franco K, Shuk E, Philip E, Blanch-Hartigan D, Parker PA, Matasar M, Horwitz S, Kissane DW, Banerjee SC, Bylund CL. Journal of Psychosocial Oncology. March 2017 http://www.tandfonline.com/doi/abs/10.1080/07347332.2017.1313352
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Gunjan L. Shah, Michael Scordo, Sean Devlin, Joachim Yahalom, Matthew J Matasar, Alison Moskowitz, Sergio A. Giralt, Craig H. Moskowitz. Biology of Blood and Bone Marrow Transplant. 2017 Volume 23 Issue 3 (S142- S143) http://www.bbmt.org/article/S1083-8791(16)30808-4/fulltext
Kara Franco, Elyse Shuk, Errol Philip, Danielle Blanch-Hartigan, Patricia A. Parker, Matthew Matasar, Steven Horwitz, David Kissane, Smita C. Banerjee, and Carma L. Bylund, Communication between oncologists and lymphoma survivors during
follow-up consultations: A qualitative analysis JOURNAL OF PSYCHOSOCIAL ONCOLOGY 0 , ISS. JA,0 2017
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024.PMID: 27713090 https://www.ncbi.nlm.nih.gov/pubmed/27713090
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. Andreas Rimner MD, Shina Lovie MPH, Meier Hsu MS, Monica Chelius BS, Zhiganh Zhang PhD, Karen Chau AB, Alison J Moskowitz MD, Matthew Matasar MD, Craig Moskowitz MD, Joachim Yalhalom MD. International Journal of Radiation Oncology. 2017 volume 97 Issue 5 (1066-1076) http://www.redjournal.org/article/S0360-3016(17)30285-7/abstract
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. J Clin Oncol. 2017 Feb:JCO2016690198. [Epub ahead of print]PMID:28029326 http://ascopubs.org/doi/abs/10.1200/JCO.2016.69.0198
Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post- Rituximab Era. Batlevi, C., Alperovich, A., Smith, K., Ying, Z., Soumerai, J. D., Copeland, A. R., Joffe, E., Caron, P., Drullinsky, P., Gerecitano, J. F., Hamilton, A., Hamlin, P. A., Horwitz, S. M., Intlekofer, A. M., Kumar, A., Matasar, M. J., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, M. L., Portlock, C. S., Sauter, C. S., Straus, D. J., Zelenetz, A. D., Ni, A., Seshan, V. E., & Younes, A. Blood, 128(22), 4119. http://www.bloodjournal.org/content/128/22/4119
What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)? Engel-Nitz, N., Dacosta Byfield, S., Bancroft, T., Amy, J., Reyes, C., Chen, M., & Matasar, M. J. Blood, 128(22), 5957. http://www.bloodjournal.org/content/128/22/5957
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Vardhana, S. A., Sauter, C. S., Matasar, M. J., Zelenetz, A. D., Galasso, N., Woo, K. M., Zhang, Z. and Moskowitz, C. H.16 Dec 2016 Br J Hematology. doi:10.1111/bjh.14453 http://onlinelibrary.wiley.com/doi/10.1111/bjh.14453/full
Maria Gil-Cupello BA, Gunjan L. Shah MD MS, Molly A. Maloy MS, Debra A. Goldman MS, Sean M. Devlin PhD, Matthew J. Matasar MD MS, Sergio Giralt MD, Craig S. Sauter MD, Craig H. Moskowitz MD, Miguel- Angel Perales MD. Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after
Autologous Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation , Volume 22 ,Issue 3 , S232 – S233 https://www.ncbi.nlm.nih.gov/pubmed/27982423
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL, Yahalom J, Matasar MJ, Verwys SL, Goldman DA, Bantilan KS, Zhang Z, McCall SJ, Moskowitz AJ, Moskowitz CH.Br J Haematol. 2016 Nov;175(3):440-447. doi: 10.1111/bjh.14245.PMID: 27377168Late Cardiac Effects of Therapy for Hodgkin Lymphoma, Matasar M, Gupta D. Clin Oncol. 2016; 1: 1042. http://www.clinicsinoncology.com/pdfs_folder/cio-v1-id1042.pdf
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation. Maria Gil-Cupello BA, Gunjan L. Shah MD MS, Molly A. Maloy MS, Debra A. Goldman MS, Sean M. Devlin PhD, Matthew J. Matasar MD MS, Sergio Giralt MD, Craig S. Sauter MD, Craig H. Moskowitz MD, Miguel-Angel Perales MD. Biology of Blood and Marrow Transplantation , Volume 22 , Issue 3 , S232 – S233 http://www.bbmt.org/article/S1083- 8791(15)01398-1/abstract
Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. Soumerai, J. D., Bantilan, K. S., Ni, A., Batlevi, C., Alperovich, A., Smith, K., Ying, Z., Copeland, A. R., Matasar, M. J., Straus, D. J., Gerecitano, J. F., Hamlin, P. A., Horwitz, S. M., Portlock, C. S., Palomba, M. L., Moskowitz, C. H., Moskowitz, A. J., Noy, A., Sauter, C. S., Kumar, A., Intlekofer, A. M., Caron, P., Drullinsky, P., Younes, A., & Zelenetz, A. D. Blood, 128(22), 1777 http://www.bloodjournal.org/content/128/22/1777
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood- 2016-03-703470. PMID: 27458003 http://www.bloodjournal.org/content/128/11/1458
Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588 30. Sauter, C. S., Verwys, S. L., McCall, S. J., Miller, S. T., Courtien, A. I., Schoder, H., Harris, P., Matasar, M. J., Younes, A., & Moskowitz, C. H. Blood, 128(22), 4198. http://www.bloodjournal.org/content/128/22/4198?sso-checked=true
Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. 32. Alperovich, A., Batlevi, C., Smith, K., Ying, Z., Soumerai, J. D., Copeland, A. R., Joffe, E., Caron, P., Drullinsky, P., Gerecitano, J. F., Hamilton, A., Hamlin, P. A., Horwitz, S. M., Intlekofer, A. M., Kumar, A., Matasar, M. J., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, M. L., Portlock, C. S., Sauter, C. S., Straus, D. J., Zelenetz, A. D., Ni, A., Seshan, V. E., & Younes, A. Blood, 128(22), 2955. http://www.bloodjournal.org/content/128/22/2955
Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning, Michael Scordo MD, Valkal Bhatt PharmD, Meier Hsu MS, Antonio M. Omuro MD, Matthew J. Matasar MS MD, Lisa DeAngelis MD, Parastoo Dahi MD, Craig H. Moskowitz MD, Sergi Giralt MD, Craig S. Sauter MD. Biology of Blood and Marrow Transplantation , Volume 22 , Issue 3 , S132 – S133 http://www.bbmt.org/article/S1083-8791(15)01222-7/abstract
Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. Parker PA, Banerjee SC, Matasar MJ, Bylund CL, Franco K, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane DW. BMJ Open. 2016 Jun 28;6(6):e011581. doi: 10.1136/bmjopen-2016-011581. PMID: 27354079 https://www.ncbi.nlm.nih.gov/pubmed/27354079
Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging. Pun SC, Plodkowski A, Matasar MJ, Lakhman Y, Halpenny DF, Gupta D, Moskowitz C, Kim J, Steingart R, Weinsaft JW. J Am Heart Assoc. 2016 May 4;5(5). pii: e003368. doi: 10.1161/JAHA.116.003368.PMID: 27146445 https://www.ncbi.nlm.nih.gov/pubmed/27146445
Cancer and Fertility Program Improves Patient Satisfaction With Information Received. Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, Matasar MJ, Noy A, Goldfarb SB. J Clin Oncol. 2016 May 20;34(15):1780-6. doi: 10.1200/JCO.2015.64.5168. PMID: 27044937 http://ascopubs.org/doi/abs/10.1200/JCO.2015.64.5168
Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. PMID: 26719374 http://jaha.ahajournals.org/content/5/5/e003368.short
Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship. Banerjee SC, Matasar MJ, Bylund CL, Horwitz S, McLarney K, Levin T, Jacobsen PB, Parker P, Astrow A, Kissane DW. Transl Behav Med. 2015 Dec;5(4):393-400. doi: 10.1007/s13142-015-0326-z. PMID: 26622912 https://www.ncbi.nlm.nih.gov/pubmed/26622912
Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Dang, T. O., Ni, A., Gerecitano, J. F., Hamlin, P. A., Hohl, T. M., Kumar, A., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, L., Portlock, C. S., Matasar, M. J., Younes, A., Zelenetz, A. D., & Straus, D. J. ). Blood (2016), 128(22), 1778. http://www.bloodjournal.org/content/128/22/1778
Imaging for Staging and Response Assessment in Lymphoma. Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J. Radiology. 2015 Aug;276(2):323-38. doi: 10.1148/radiol.2015142088. Review. PMID: 26203705 https://www.ncbi.nlm.nih.gov/pubmed/26203705
Tissue characteristics and anatomic distribution of cardiac metastases among patients with advanced systemic cancer assessed by cardiac magnetic resonance (CMR) Shawn Pun 1 , Andrew Plodkowski 3 , Dipti Gupta 1 , Yuliya Lakhman 3 , Darragh F Halpenny 3 , Matthew J Matasar 2 , Angel Chan 1 , Jennifer Liu 1 , Richard Steingart 1 and Jonathan W Weinsaft 1.Journal of the American Heart Association. 2016;5:e003368, originally published May 4, 2016 http://go.galegroup.com/ps/anonymous?p=AONE&sw=w&issn=10976647&v=2.1&it=r&id=GALE%7CA45271 6919&sid=googleScholar&linkaccess=fulltext&authCount=1&isAnonymousEntry=true
Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell, Soumerai, J. D., Zelenetz, A. D., Moskowitz, C. H., Younes, A., Palomba, M. L., Hamlin, P. A., Noy, A., Horwitz, S. M., Matasar, M. J., Moskowitz, A. J., Portlock, C. S., Straus, D. J., Chen, A., Little, R. F., France, F., Whang, J., Mishra, N., Jarjies, C., & Gerecitano, J. F. . Blood, 126(23), 2691 http://www.bloodjournal.org/content/126/23/2691
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. Blood. 2015 Apr 16;125(16):2579-81. doi: 10.1182/blood-2014-10- 606939. PMID: 25758829 https://www.ncbi.nlm.nih.gov/pubmed/25758829
Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) Buzaglo, J. S., Miller, M. F., Karten, C., Weiss, E. S., Tomlinson, , Andersen, B. L., Matasar, M. J., Byrd, J. C., & Flowers, C. (2016). Blood, 128(22), 5970 http://www.bloodjournal.org/content/128/22/5970
A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas 33.Mehta-Shah, N., Moskowitz, A. J., Lunning, M., Lynch, P., Scheuerman, M., Kumar, A., Gerecitano, J. ,
Zelenetz, A. D., Hamlin, P. A., Noy, A., Matasar, M. J., et al. (2016). Blood, 128(22), 2991 http://www.bloodjournal.org/content/128/22/2991?sso-checked=true
Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States Matasar, M. J., Dacosta Byfield, S., Blauer-Peterson, C., Montez, M., Reyes, C., & Masaquel, A. (2016). Blood, 128(22), 5928 http://www.bloodjournal.org/content/128/22/5928
Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. Blood (2016) Herrera, A. F., Matasar, M. J., Assouline, S., Kamdar, M., Mehta, A., Fleury, I., Kim, W. S., Kim, T. M., Bosch, F., Radford, J. A., Bu, L., Hong, W., & Sehn, L. H. Blood 128(22), 4194 http://www.bloodjournal.org/content/128/22/4194?sso- checked=true
VINCRISTINE OMISSION, BUT NOT DOSE REDUCTION, IS ASSOCIATED WITH DECREASED SURVIVAL IN ELDERLY DLBCL PATIENTS, S. Afifi; A. Michael; M. Azimi; M. Rodriguez; Z. Zhang;
Woo; C. H. Moskowitz; A. Moskowitz; A. Kumar; M. J. Matasar; C. S. Portlock; A. D. Zelenetz; L. Palomba; A. Noy; J. Gerecitano; S. M. Horwitz; D. J. Straus; A. Younes; P. A. Hamlin. Hematological Oncology. 33():212–213, Jun 2015 http://insights.ovid.com/hematological- oncology/honc/2015/06/001/vincristine-omission-not-dose-reduction-associated/236/01445428
Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Batlevi, C., Rapaport, F., Intlekofer, A. M., Reiner, A., Moskowitz, C. H., Horwitz, S. M., Zelenetz, A. D., Palomba, L., Moskowitz, A. J., Gerecitano, J. F., Hamlin, P. A., Copeland, A. R., Matasar, M. J., Sauter, C. S., et al. (2015). Blood (2015), 126(23), 2668 http://www.bloodjournal.org/content/126/23/2668?sso-checked=true
Are we ready to predict late effects? A systematic review of clinically useful prediction models. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ. Eur J Cancer. 2015 Apr;51(6):758-66. doi: 10.1016/j.ejca.2015.02.002. Review. https://www.ncbi.nlm.nih.gov/pubmed/25736818
A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning. Scordo, M., Bhatt, V., Hsu, M., Omuro, A. M., Matasar, M. J., DeAngelis, L., Dahi, P. B., Moskowitz, C. H., Giralt, S. A., & Sauter, C. S Blood, 126(23), 4354. http://www.bloodjournal.org/content/126/23/4354
A PHASE I/II TRIAL OF THE COMBINATION OF ROMIDEPSIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA AND MYELOMA. N. Mehta-Shah; M. A. Lunning; J. Ruan; S. Nair; A. M. Boruchov; A. J. Moskowitz; J. F. Gerecitano; P. A. Hamlin; J. P. Leonard; P. Lynch; J. Matasar; C. Moskowitz; C. Portlock; A. Younes; P. Myskowski; P. Nolan; M. L. Palomba; J. Vredenburgh; C. Querfeld; D. J. Straus; A. Zelenetz; H. Schroder; J. Rademaker; W. Schaffer; S. M. Horwitz. Hematological Oncology. 33():108, Jun 2015 http://insights.ovid.com/hematological-oncology/honc/2015/06/001/phase-ii-trial- combination-romidepsin-lenalidomide/35/01445428
CLINICAL, METABOLIC AND MOLECULAR RESPONSES WITH SEQUENTIAL R-CHOP, HIGH-DOSE CYTARABINE, AND IODINE-131 TOSITUMOMAB-BASED TRANSPLANT IN MANTLE CELL LYMPHOMA A. D. Zelenetz; S. F. Schoninger; C. Sauter; G. Ulaner; C. Casulo; M. Faham; K. Kong; A. Dogan; R. Grewal; J. Gerecitano; J. Goldberg; A. Hamilton; P. Hamlin; M. Matasar; C. Moskowitz; A. Noy; Palomba; C. S. Portlock; A. Younes; T. Willis; A. Kumar. Hematological Oncology. 33():206, Jun 2015 http://insights.ovid.com/hematological-oncology/honc/2015/06/001/clinical-metabolic-molecular-responses- sequential/223/01445428
Toxicity of Maintenance Rituximab in Older Adults with Non-Hodgkin Lymphoma. Matasar, M. J., Atoria, C. L., Elkin, E. B., & Nabhan, C. (2015). Blood, 126(23), 881. http://www.bloodjournal.org/content/126/23/881
Late morbidity and mortality in patients with Hodgkin’s lymphoma treated during adulthood. Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. J Natl Cancer Inst. 2015 Feb 24; -2008 107(4). pii: djv018. doi: 10.1093/jnci/djv018. PMID: 25717170 https://www.ncbi.nlm.nih.gov/pubmed/25717170
